Date:1/23/2009

forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding ATPace's expected entry into a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia and the anticipated results of the trial, CDP-1050's expected commencement of a Phase 2 safety clinical trial in heart failure patients. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Such risks include the risk that the clinical trial for approval of ATPace and the Phase 2 clinical trial for our CDP-1050 investigational drug may not be successful, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, and that our technology may not lead to expected results including the development or the successful commercialization of technologies relating to the use of ATP or nitric oxide. Additional uncertainties and risks are described in Cordex's most recently filed SEC documents, such as its most recent annual report on Form
'/>"/>

SOURCE Cordex Pharma, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Axikin Pharmaceuticals Spins out of Actimis
2. Asbestos, Pharmaceutical Liability, Construction Defects, Nanotech: Covered by Targeted CLE Teleconferences
3. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
4. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
5. Cracking the Code: Exclusive Conference to Reveal Secrets of Chinese Pharmaceutical Industry
6. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
7. Cumberland Pharmaceuticals Appoints Lee Product Director
8. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
9. ERYtech Pharma Signs an Agreement With the Penn Jersey Region of American Red Cross
10. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing